Working Together for Personalized Medicine 

Strategic Business Opportunities with Agendia

Agendia’s unique culture and leadership position in molecular diagnostics provides unique opportunities for mutual commercial collaboration success. Our business development mission is to quickly assess and execute on opportunities which utilize our core competencies to generate value through successful managed health care in cancer.

Companion Diagnostic Development, FDA Clearance and Commercialization

Agendia seeks to work with a limited number of pharmaceutical oncology groups to expedite programs in companion diagnostics. We are seeking partners who recognize our unique strategic scientific foundation and experience in developing FDA-cleared In-vitro Diagnostic Multivariate Index Assays (IVDMIA) and their successful commercialization.

Clinical Trial Patient Stratification by Risk Profile and Predicted Outcome

Agendia applies its current IVDMIA solutions to clinical trials. Publically available examples of our leadership in clinical trials are the MINDACT and I-SPY trials which utilize MammaPrint as a means of frontline stratification for six, late stage cancer therapeutics.

In-licensing Prognostic and Predictive Gene Expression Biomarker

Agendia actively evaluates in-licensing opportunities for well validated, genomic biomarkers with   high-value clinical utility. With a proven track record of rapid validation and commercialization of novel cancer assays and diagnostic panels¸ combined with our successful FDA IVDMIA experience, Agendia sets the standard as an in-licensing partner.

Collaborative Development: Patient Sample to Diagnosis Process Enhancement

Agendia’s business is built on the core competencies of our founders’ world-renowned research and clinical experience in the field of genomics. Agendia’s culture is unique in terms of its unbiased scientific approach, pairing the optimum methodologies with disruptive technologies, to achieve ground-breaking, clinically meaningful results. We apply a “best in class” approach to maintain a leadership position in the rapidly evolving field of molecular diagnostics.  We are committed to providing accurate, clinically relevant, diagnostic assays to physicians and their patients.

For more information, contact Agendia Business Development.